UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 000-17999

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

c/o AbbVie, Inc.

1 North Waukegan Road

North Chicago, Illinois 60064

(847) 932-7900
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, par value $0.01 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   x
Rule 12g-4(a)(2)   ¨
Rule 12h-3(b)(1)(i)   x
Rule 12h-3(b)(1)(ii)   ¨
Rule 15d-6   ¨
Rule 15d-22(b)   ¨

 

Approximate number of holders of record as of the certification or notice date:

 

Common Stock, par value $0.01 per share: 1

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, ImmunoGen, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date:  February 22, 2024 ImmunoGen, Inc.
     
  By: /s/ Emily Weith
  Name: Emily Weith
  Title: Secretary

 

 

 

Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di ImmunoGen
Grafico Azioni ImmunoGen (NASDAQ:IMGN)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di ImmunoGen